Get the Stockscreener App
2.39
8.08%
-0.21
After Hours:
2.47
0.08
+3.35%
Protalix BioTherapeutics Inc. Stock (PLX) Forecast
The Protalix BioTherapeutics Inc. (PLX) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $0.8876, representing a -62.86% decrease from the current price of $2.39. The highest analyst price target is $1.7611, and the lowest is $0.0142.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month PLX Price Target
Average 2.4255
(+1.48% Upside)
Is Protalix BioTherapeutics Inc. (PLX) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 46.58 | Neutral |
| STOCH(9,6) | 65.90 | Neutral |
| STOCHRSI(14) | 11.74 | Buy |
| MACD(12,26) | 0.0458 | Buy |
| ADX(14) | 17.68 | Neutral |
| William %R | -61.36 | Neutral |
| CCI(14) | -29.98 | Neutral |
Buy: 2
Sell: 0
Neutral: 5
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
2.545
Sell
|
2.5074
Sell
|
| MA20 |
2.4295
Sell
|
2.4707
Sell
|
| MA50 |
2.4426
Sell
|
2.3675
Buy
|
| MA100 |
2.131
Buy
|
2.137
Buy
|
| MA200 |
1.6048
Buy
|
1.8578
Buy
|
Buy: 5
Sell: 5
Neutral: 0
Summary: Neutral
According to our latest analysis, PLX could be considered a Potential Buy, with 17 technical analysis indicators signaling 7 Buy signals, 5 signaling Sell signals and 5 Neutral signals. This might be a good time to open fresh positions on PLX, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 46.58 indicates that PLX is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 65.9 indicates that PLX is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 11.74 indicates that PLX is oversold. This suggests that PLX price is at or near the lowest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 17.68 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -29.98 indicates that PLX is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term PLX price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Protalix BioTherapeutics Inc. financial reports and earnings history, Protalix BioTherapeutics Inc. (PLX) stock could reach $1.6494 by 2030, $1.6098 by 2040 and $7.9479 by 2050. See the projected annual prices until 2050 of the Protalix BioTherapeutics Inc. stock below:
- Protalix BioTherapeutics Inc. (PLX) is expected to reach an average price of $0.6638 in 2035, with a high prediction of $0.6388 and a low estimate of $0.5354. This indicates an $-72.22% rise from the last recorded price of $2.39.
- Protalix BioTherapeutics Inc. (PLX) stock is projected to chart a bullish course in 2040, with an average price target of $1.0675, representing an $-55.34% surge from its current level. The forecast ranges from a conservative $1.4775 to a sky-high $1.6098.
- Our analysts predict Protalix BioTherapeutics Inc. (PLX) to jump 109.40% by 2045, soaring from $5.0046 to an average price of $5.0046, potentially reaching $4.9824. While $5.0046 is the low estimate, the potential upside is significant.
- Protalix BioTherapeutics Inc. (PLX) stock is expected to climb by 2050, reaching an average of $7.649, a $220.04% jump from its current level. However, a wide range of estimates exists, with high and low targets of $7.9479 and $7.8485, respectively, highlighting the market's uncertainty.
Protalix BioTherapeutics Inc. Stock (PLX) Year by Year Forecast
Protalix BioTherapeutics Inc. Stock (PLX) Price Forecast for 2025
Protalix BioTherapeutics Inc. Stock (PLX) is expected to reach an average price of $1.1711 in 2025, with a high prediction of $2.328 and a low estimate of $0.0142. This indicates an -51.00% fall from the last recorded price of $2.39.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| May, 2025 | $1.2826 | $0.0142 | $1.7611 | -46.34% |
| June, 2025 | $0.4688 | $0.3288 | $2.328 | -80.38% |
| July, 2025 | $1.7634 | $0.3757 | $1.8834 | -26.22% |
| August, 2025 | $1.0812 | $1.0163 | $1.7404 | -54.76% |
| September, 2025 | $1.2189 | $0.9381 | $1.745 | -49.00% |
| October, 2025 | $1.0635 | $1.0135 | $1.8658 | -55.50% |
| November, 2025 | $1.5412 | $0.9805 | $1.7212 | -35.51% |
| December, 2025 | $0.9759 | $0.8559 | $1.6752 | -59.17% |
Protalix BioTherapeutics Inc. Stock (PLX) Price Forecast for 2026
The predicted value for Protalix BioTherapeutics Inc. (PLX) in 2026 is set at an average of $2.4406. Estimates vary from a peak of $4.8367 to a trough of $0.0445, indicating an +2.12% surge from the present price of $2.39.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $1.3536 | $0.8328 | $1.7836 | -43.36% |
| February, 2026 | $1.2413 | $1.0113 | $1.7613 | -48.06% |
| March, 2026 | $1.959 | $1.1482 | $2.089 | -18.03% |
| April, 2026 | $2.9337 | $2.0529 | $4.8367 | +22.75% |
| May, 2026 | $2.9514 | $1.6575 | $3.7106 | +23.49% |
| June, 2026 | $3.1391 | $2.2603 | $3.3383 | +31.34% |
| July, 2026 | $0.6538 | $0.5238 | $4.5399 | -72.65% |
| August, 2026 | $0.1115 | $0.0445 | $1.0088 | -95.34% |
| September, 2026 | $0.2939 | $0.1216 | $0.2284 | -87.70% |
| October, 2026 | $0.5062 | $0.457 | $0.3731 | -78.82% |
| November, 2026 | $0.3285 | $0.4484 | $0.5423 | -86.26% |
| December, 2026 | $0.6138 | $0.4015 | $0.5507 | -74.32% |
Protalix BioTherapeutics Inc. Stock (PLX) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Protalix BioTherapeutics Inc. (PLX) is $0.6571, with a high forecast of $0.9522 and a low forecast of $0.3621. This indicates an -72.51% decrease from the last price of $2.39.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $0.7461 | $0.71 | $0.6661 | -68.78% |
| February, 2027 | $0.8984 | $0.7953 | $0.7392 | -62.41% |
| March, 2027 | $0.9699 | $0.9635 | $0.9231 | -59.42% |
| April, 2027 | $0.9562 | $0.9829 | $0.896 | -59.99% |
| May, 2027 | $0.7583 | $0.9483 | $0.9522 | -68.27% |
| June, 2027 | $0.8737 | $0.8809 | $0.9056 | -63.45% |
| July, 2027 | $0.6659 | $0.7329 | $0.8467 | -72.14% |
| August, 2027 | $0.5082 | $0.3621 | $0.619 | -78.74% |
| September, 2027 | $0.5236 | $0.5913 | $0.5474 | -78.09% |
| October, 2027 | $0.5459 | $0.4897 | $0.5259 | -77.16% |
| November, 2027 | $0.4982 | $0.5451 | $0.5251 | -79.16% |
| December, 2027 | $0.3485 | $0.4835 | $0.4874 | -85.42% |
Protalix BioTherapeutics Inc. Stock (PLX) Price Forecast for 2028
In 2028, Protalix BioTherapeutics Inc. (PLX) is projected to reach an average price of $1.1622, with a high projection of $2.2744 and a low estimate of $0.05. This indicates an -51.37% fall from the last price of $2.39.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $0.4558 | $0.3966 | $0.4258 | -80.93% |
| February, 2028 | $0.4767 | $0.4919 | $0.4589 | -80.06% |
| March, 2028 | $0.4534 | $0.4634 | $0.4442 | -81.03% |
| April, 2028 | $0.2607 | $0.4157 | $0.4279 | -89.09% |
| May, 2028 | $0.2411 | $0.2711 | $0.2919 | -89.91% |
| June, 2028 | $0.2766 | $0.05 | $0.3466 | -88.42% |
| July, 2028 | $0.2144 | $0.0714 | $0.3074 | -91.03% |
| August, 2028 | $0.519 | $0.1013 | $0.879 | -78.28% |
| September, 2028 | $0.9067 | $0.4259 | $0.9967 | -62.06% |
| October, 2028 | $1.9944 | $0.9436 | $2.2744 | -16.55% |
| November, 2028 | $0.9691 | $0.6522 | $2.0414 | -59.45% |
| December, 2028 | $0.7868 | $0.7568 | $1.271 | -67.08% |
Protalix BioTherapeutics Inc. Stock (PLX) Price Forecast for 2029
The 2029 price forecast for Protalix BioTherapeutics Inc. Stock (PLX) is $0.7431 on average, with a high prediction of $1.337 and a low estimate of $0.1492. This represents an -68.91% decrease from the previous price of $2.39.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $0.4214 | $0.2395 | $0.7637 | -82.37% |
| February, 2029 | $0.7792 | $0.3984 | $0.9322 | -67.40% |
| March, 2029 | $0.6469 | $0.5869 | $0.8777 | -72.93% |
| April, 2029 | $0.3846 | $0.3246 | $0.6738 | -83.91% |
| May, 2029 | $0.2792 | $0.1492 | $0.8023 | -88.32% |
| June, 2029 | $0.4269 | $0.2162 | $0.4869 | -82.14% |
| July, 2029 | $0.7747 | $0.4139 | $0.8947 | -67.59% |
| August, 2029 | $0.4793 | $0.4624 | $0.8516 | -79.95% |
| September, 2029 | $0.507 | $0.4601 | $0.5901 | -78.79% |
| October, 2029 | $0.3617 | $0.3517 | $0.7509 | -84.87% |
| November, 2029 | $0.2694 | $0.2094 | $0.4625 | -88.73% |
| December, 2029 | $1.68 | $0.2163 | $1.337 | -29.71% |
Protalix BioTherapeutics Inc. Stock (PLX) Price Forecast for 2030
Protalix BioTherapeutics Inc. Stock (PLX) is expected to reach an average price of $2.2958 in 2030, with a high forecast of $3.3974 and a low forecast of $1.1941. This signifies an -3.94% decrease from the last price of $2.39.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $1.5107 | $1.7107 | $1.6494 | -36.79% |
| February, 2030 | $1.3923 | $1.1941 | $1.2063 | -41.75% |
| March, 2030 | $1.9258 | $1.9414 | $1.8097 | -19.42% |
| April, 2030 | $3.4444 | $3.2583 | $3.0464 | +44.12% |
| May, 2030 | $3.3921 | $3.4917 | $3.3221 | +41.93% |
| June, 2030 | $3.1687 | $3.4087 | $3.3974 | +32.58% |
| July, 2030 | $2.8464 | $3.142 | $3.1473 | +19.10% |
| August, 2030 | $2.735 | $2.3727 | $2.395 | +14.43% |
| September, 2030 | $1.1696 | $1.3395 | $2.1411 | -51.06% |
| October, 2030 | $1.8403 | $1.6741 | $1.4868 | -23.00% |
| November, 2030 | $2.7548 | $1.8625 | $2.1848 | +15.26% |
| December, 2030 | $2.8194 | $2.7733 | $2.7195 | +17.97% |
10.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):